Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive October 1, 2011	30 Years of Pharma: Perspective in Numbers Top 10 pharmaceutical products worldwide.
The Motley Fool December 19, 2011 Matt Koppenheffer	What's Ahead for Regions Financial in 2012? Regions Financial's stock took a tumble in 2011; will the new year offer comeback potential?
InternetNews April 19, 2011	Microsoft Office 365 Moves to Public Beta If 10,000 beta testers for the upgraded online application services is good, millions have to be that much better.
Pharmaceutical Executive November 1, 2011 Josef Bossart	Pharma Revolution Recalibrated Industry critics point to a lag in NME approvals as proof of innovation stagnation, but combination products and new delivery systems are quietly saving lives, and bringing in big dollars.
Managed Care August 2004	MCOs, Drug Manufacturers Have Lots of PR Work to Do Managed care companies, and pharmaceuticals especially, receive disheartening numbers in a consumer satisfaction poll.
The Motley Fool May 25, 2006 Stephen D. Simpson	AmSouth and Regions' Mediocre Merger Hopefully, the combined bank will be more like AmSouth than Regions. Good luck, AmSouth shareholders. You might deserve better than this.
Managed Care April 2004	Headlines on Deadline The least insured of the major medical services is the pharmaceutical benefit, according to the Pharmaceutical Research and Manufacturers of America.
The Motley Fool December 16, 2011 Matt Koppenheffer	Regions Financial's Stock Was Clobbered by 2011 It was a tough year for Regions Financial shareholders.
The Motley Fool January 11, 2012 Shubh Datta	Region Financial's Morgan Keegan May Finally Be Sold Regions hopes to sell Morgan Keegan by next week.
The Motley Fool January 25, 2007 Brian Lawler	Johnson & Johnson's Earnings Glee Johnson & Johnson keeps growing, even if the pharmaceutical segment is a bit sluggish. Investors, take note.
The Motley Fool December 6, 2004 Brian Gorman	Pill-Popping Nation Americans are using more prescription drugs. Unfortunately for big pharma investors, pharmaceutical companies' benefits from these trends are tempered by other factors.
The Motley Fool October 17, 2006 Brian Lawler	Roche Rocks The Swiss pharma has a stable of hot brands and lots of promise in the pipeline. Investors, this may be a pharmaceutical worth looking at.
The Motley Fool July 25, 2011	West Pharmaceutical Services Earnings Preview West Pharmaceutical Services will unveil its latest earnings on Thursday, July 28.
Managed Care July 2006	Physician Satisfaction Study Surprises A new study suggests that physicians working in areas where there is an extensive medical infrastructure are less happy with the quality of the care they provide than doctors working elsewhere.
The Motley Fool July 20, 2006 Stephen D. Simpson	Wyeth Wins Again Another respectable quarter and a decent pipeline make this pharmaceutical stock worth watching.
The Motley Fool January 24, 2006 Stephen D. Simpson	Reddy, Set, Go! After a tough stretch, leading Indian pharmaceutical company Dr. Reddy's may be ready to move again. This is still a turnaround story, though, so investors unable or unwilling to assume above-average risk should probably steer clear.
The Motley Fool August 3, 2011 Shubh Datta	Regions Financial Is Bouncing Back Regions Financial posted strong second quarter results as provision for loan losses fell and credit quality improved.
The Motley Fool January 19, 2006 Stephen D. Simpson	Novartis Marches On While reported profits are masked by some charges, this Swiss drug company is still delivering the goods. Throw in a solid pipeline and a reasonable valuation, and the stock could still be worth a look for new money in the pharmaceutical space.
The Motley Fool July 28, 2011	Medicis Pharmaceutical Earnings Preview Medicis Pharmaceutical will unveil its latest earnings on Tuesday, August 2.
The Motley Fool July 18, 2011 Travis Hoium	Pharmaceutical Product Development Shares Popped: What You Need to Know Shares of research group Pharmaceutical Product Development jumped as much as 18% this morning on potential merger talks.
The Motley Fool October 11, 2005 Stephen D. Simpson	Genentech Generates Profits Whether you call it a biotech or a pharmaceutical, there's no disputing that Genentech is raking in some big bucks. Trying to value this stock is no treat, but growth-oriented investors should still have much to look forward to over the years.
The Motley Fool December 2, 2011 Shubh Datta	Housing Crisis Still Haunts Regions Regions Financial's fourth straight quarterly profit fails to satisfy the Street.
The Motley Fool January 22, 2007 Ryan Fuhrmann	Regions Financial Stays Close to Home Investors, it's time to keep an eye on this active banking-industry player.
Reason October 2005 Ronald Bailey	Data: Aiding and Indebting Despite the push to give to sub-Saharan African economies, evidence that aid boosts economic development is hard to come by.
CRM February 2, 2003 David Myron	Vertical Focus: Pharmaceuticals Pharmaceutical companies are prolonging the good health of their customers -- and the CRM industry. Largely influenced by retiring Baby Boomers, lack of FDA-approved drugs in the pipeline, and direct selling campaigns, the industry is becoming more customer-focused.
The Motley Fool April 8, 2008 Brian Lawler	FDA Approvals ... Increase? So far in 2008, the agency has given more drugs a thumbs-up than this time in 2007. Take a look at which companies received approvals.
The Motley Fool January 27, 2011 Seth Jayson	Here's How Pharmaceutical Product Development May Be Failing You Here's the current margin snapshot for Pharmaceutical Product Development and some of its sector and industry peers and direct competitors.
Information Today October 2000	Dialog One Releases New Pharmaceutical Module With Dialog One Pharmaceutical, users can discover what new drugs their competitors have in development, follow regulatory information for pharmaceuticals and medical devices, and uncover lucrative drug licensing opportunities worldwide...
InternetNews July 27, 2010	Oracle Debuts Drug-Tracking App for Big Pharma With its new Pedigree and Serialization Manager, Oracle is pitching an application to pharmaceutical companies that will enable them to track the movement of drugs across the supply chain.
The Motley Fool July 18, 2007 Ryan Fuhrmann	Further Savings for Regions Financial Regions Financial continues to wring savings from a recent merger. Investors, take note.
The Motley Fool January 26, 2005 Stephen D. Simpson	Sanofi's Balancing Act A broad portfolio of drugs helps the French pharmaceutical stay ahead of its peers. It's a good option for investors who want a strong growth stock in the pharmaceutical space but don't want to take on the risks of turnarounds or litigation.
The Motley Fool April 15, 2008 Ryan Fuhrmann	Regions Financial Is Saved Regions Financial posts a steady quarter in a tough banking environment.
The Motley Fool February 12, 2007 Brian Lawler	I Love Drug Stocks This Valentine's Day, leave a special place in your heart for drug stocks.
IEEE Spectrum May 2010 Dana Mackenzie	Digitally Divided Newly developed countries favor new media, but Western nations still buy more
The Motley Fool February 22, 2005 Rich Duprey	Merger Mania Besets Japanese Pharmaceuticals A new law spurs megamergers in Japan's pharmaceutical industry. Stocks of companies seen as particularly interesting, including Eisai, Mitsubishi Pharma, and Shionogi, all jumped more than 2%.
The Motley Fool October 27, 2005 Stephen D. Simpson	A Balanced Attack for Glaxo A broad suite of drugs, a huge sales force, and a solid pipeline make GlaxoSmithKline an appealing pharmaceutical company. The problem for investors is that it's all valued into the stock.
The Motley Fool December 27, 2007 Brian Orelli	Drugmaker Growth: The China Connection Just like other industries, the pharmaceutical industry has realized that China is a good place to find cheap labor. While reluctant to set up FDA-regulated manufacturing plants in China, other stages of drug development can be done there.
The Motley Fool September 25, 2008 Brian Lawler	Eli Lilly's Dose of Disclosure The pharmaceutical pledges public reports of its dealings with doctors.
The Motley Fool July 11, 2007 Brian Lawler	Not All Pharmaceutical Markets Are the Same The case of China's former FDA leader highlights the issues facing the country's pharmaceutical industry. Investors, take note.
The Motley Fool May 1, 2007 Ryan Fuhrmann	Unattractive Beauty at Avon Avon is sitting pretty in turnaround efforts, but the stock price may reflect this already.
PC Magazine February 14, 2007	Fun Facts: Worldwide Internet Usage There are an estimated 1.1 billion Internet users worldwide.
The Motley Fool August 17, 2007 Brian Orelli	Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully.
Chemistry World August 10, 2007 Hepeng Jia	China Invests More Than $1 Billion in Drug Safety In a bid to improve its food and drug safety, China has announced it will invest 8.8 billion yuan (US$1.16 billion) in the coming four years to improve its food and drug inspection and monitoring infrastructure.
Reason November 2003 Ronald Bailey	Envy Your Kids In less than a lifetime, the $10.7 trillion U.S. economy could grow more than 12-fold, to $128.6 trillion by 2077, according to a new report issued by the nonpartisan Employment Policy Foundation. Real U.S. per capita personal income could rise fivefold, from $31,384 today to $155,632 in 2077.
Chemistry World June 24, 2011 Hepeng Jia	Pharma pollution is out of control in China Active pharmaceutical ingredients pollution problems seem to continue even after the Chinese government increased efforts to reduce environmental pollution from drug makers.
The Motley Fool June 11, 2007 Brian Lawler	Johnson & Johnson's Pretty Pipeline While there are concerns about other parts of Johnson & Johnson (for example, its medical device segment), its pharmaceutical division has a robust pipeline of compounds in development that should pay off in the long haul.
The Motley Fool February 4, 2008 Chuck Saletta	Best International Stock: Teva Pharmaceutical A quick summary of Israel's Teva Pharmaceutical, the world's largest generic drugmaker.
The Motley Fool October 26, 2005 Stephen D. Simpson	Cardinal's Tweet More Sweet Changes at the giant manufacturer, distributor, and service provider in the health-care industry are working out well, but the stock price already reflects it.
Reason December 2005 Ronald Bailey	Data: Escape from Poverty In 2000 the world's eight richest nations set the Millennium Development Goals... Average annual global per capita income fell, in real dollars, from $445 in 1 A.D. to $436 in 1000 A.D. By 1820 it had increased to $667... etc.
The Motley Fool March 29, 2011 Brian Orelli	Medtronic's Exciting New Toys The device maker received multiple approvals in less than a week.